InRange webinar bytes 4: Conclusions and implications by Dr. Pratic Choudhary

Time in Range is the most recent and upcoming glycemic marker in the management of diabetes. InRange study is one of the first studies to use continuous glucose monitoring metrics as the primary end point to compare second-generation basal insulin analogues, Glargine 300 U/m and Degludec 100 U/ml in persons with type 1 diabetes. Watch Dr. Pratik Chaudhary discuss the implications of the outcomes of this study and its relevance in the day to day practice of a physician.